INXBNASDAQHealthcare · Biotechnology

Inhibrx Biosciences, Inc.

$15.86+13.94%(+$1.94)

TickerSpark Score

43/100

Weak

Valuation

Profitability

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INXB research report →

52-Week Range49% of range

Low $12.95

Current $15.86

High $18.95

Companyinhibrx.com

Inhibrx Biosciences, Inc. , a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma.

CEO: Mark Paul Lappe
IPO: 2018
Employees: 166
HQ: La Jolla, CA, US

Price Chart

+1.80% · this period

Valuation

Market Cap: $225.87M
P/E: -13.17
P/S: 1241.52
P/B: -81.51
EV/EBITDA: -12.45
Div Yield: 0.00%

Profitability

Gross Margin: -35.62%
Op Margin: -9465.46%
Net Margin: -10014.23%
ROE: -563.89%
ROIC: -76.97%

Performance & Tape

52W High: $18.95
52W Low: $12.95
50D MA: $16.45
200D MA: $16.45
Beta: 2.88
Avg Volume: 440.58K

Get TickerSpark's AI analysis on INXB

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime